Abstract
Glucocorticosteroids are the most effective anti-inflammatory therapy for asthma but are relatively ineffective in COPD. Glucocorticoids are broad-spectrum anti-inflammatory drugs that suppress inflammation via several molecular mechanisms. Glucocorticoids suppress the multiple inflammatory genes that are activated in asthma by reversing histone acetylation of activated inflammatory genes through binding of ligand-bound glucocorticoid receptors (GR) to coactivator molecules and recruitment of histone deacetylase-2 (HDAC2) to the activated inflammatory gene transcription complex (trans-repression). At higher concentrations of glucocorticoids GR homodimers interact with DNA recognition sites to activate transcription through increased histone acetylation of anti-inflammatory genes and transcription of several genes linked to glucocorticoid side effects (trans-activation). Glucocorticoids also have post-transcriptional effects and decrease stability of some proinflammatory mRNAs. Decreased glucocorticoid responsiveness is found in patients with severe asthma and asthmatics who smoke, as well as in all patients with COPD. Several molecular mechanisms of glucocorticoid resistance have now been identified which involve phosphorylation and other post-translational modifications of GR. HDAC2 is markedly reduced in activity and expression as a result of oxidative/nitrative stress and pi3 kinase-δ inhibition, so that inflammation is resistant to the anti-inflammatory actions of glucocorticoids. Dissociated glucocorticoids and selective GR modulators which show improved trans-repression over trans-activation effects have been developed to reduce side effects, but so far it has been difficult to dissociate anti-inflammatory effects from adverse effects. In patients with glucocorticoid resistance alternative anti-inflammatory treatments are being investigated as well as drugs that may reverse the molecular mechanisms of glucocorticoid resistance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR (2006) Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203(8):1883–1889
Adcock IM, Lane SJ, Brown CA, Lee TH, Barnes PJ (1995) Abnormal glucocorticoid receptor/AP-1 interaction in steroid resistant asthma. J Exp Med 182:1951–1958
Barnes PJ (2002) Scientific rationale for combination inhalers with a long-acting b2-agonists and corticosteroids. Eur Respir J 19:182–191
Barnes PJ (2005) Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin Ther Targets 9(6):1111–1121
Barnes PJ (2006) Corticosteroids: the drugs to beat. Eur J Pharmacol 533:2–14
Barnes PJ (2007) Scientific rationale for using a single inhaler for asthma control. Eur Respir Dis 29:587–595
Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183–192
Barnes PJ (2009) Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71:451–464. doi:10.1146/annurev.physiol.010908.163257
Barnes PJ (2010a) Inhaled corticosteroids in COPD: a controversy. Respiration 80(2):89–95. doi:10.1159/000315416
Barnes PJ (2010b) Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 120(2-3):76–85
Barnes PJ (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol 163(1):29–43. doi:10.1111/j.1476-5381.2010.01199.x
Barnes PJ (2013a) Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 131:636–645
Barnes PJ (2013b) New anti-inflammatory treatments for chronic obstructive pulmonary disease. Nat Rev Drug Discov 12:543–559
Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 342:1905–1917
Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids: an update. Am J Respir Crit Care Med 157:S1–S53
Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML (2001) Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166(3):1975–1982
Bergmann MW, Staples KJ, Smith SJ, Barnes PJ, Newton R (2004) Glucocorticoid inhibition of GM-CSF from T cells is independent of control by NF-kB and CLE0. Am J Respir Cell Mol Biol 30:555–563
Bhavsar P, Hew M, Khorasani N, Alfonso T, Barnes PJ, Adcock I, Chung KF (2008) Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared to non-severe asthma. Thorax 63:784–790
Black JL, Oliver BG, Roth M (2009) Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting beta-agonists. Chest 136(4):1095–1100. doi:10.1378/chest.09-0354
Charmandari E, Kino T, Chrousos GP (2013) Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity. Endocr Dev 24:67–85. doi:10.1159/000342505
Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–695
Culpitt SV, Nightingale JA, Barnes PJ (1999) Effect of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1635–1639
Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Fielding S, Gompertz S, Haughney J, Lee AJ, McCormack K, McPherson G, Morice A, Norrie J, Sullivan A, Wilson A, Price D (2015) Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials 16:267. doi:10.1186/s13063-015-0782-2
Donn R, Berry A, Stevens A, Farrow S, Betts J, Stevens R, Clayton C, Wang J, Warnock L, Worthington J, Scott L, Graham S, Ray D (2007) Use of gene expression profiling to identify a novel glucocorticoid sensitivity determining gene, BMPRII. FASEB J 21(2):402–414
Dostert A, Heinzel T (2004) Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 10(23):2807–2816
Erin EM, Zacharasiewicz AS, Nicholson GC, Tan AJ, Neighbour H, Engelstatter R, Hellwig M, Minn KO, Barnes PJ, Hansel TT (2008) Rapid anti-inflammatory effect of inhaled ciclesonide in asthma: a randomised, placebo-controlled study. Chest 134:740–745
Evans DJ, Cullinan P, Geddes DM (2001) Cyclosporin as an oral corticosteroid sparing agent in stable asthma (Cochrane Review). Cochrane Database Syst Rev 2, CD002993
Fakhri S, Tulic M, Christodoulopoulos P, Fukakusa M, Frenkiel S, Leung DY, Hamid QA (2004) Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model. Laryngoscope 114(5):887–892
Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P (2014) Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med. doi:10.1016/s2213-2600(14)70169-9
Ford PA, Durham AL, Russell REK, Gordon F, Adcock IM, Barnes PJ (2010) Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338–1344
Galigniana MD, Piwien-Pilipuk G, Assreuy J (1999) Inhibition of glucocorticoid receptor binding by nitric oxide. Mol Pharmacol 55(2):317–323
Garnock-Jones KP (2015) Roflumilast: a review in COPD. Drugs 75(14):1645–1656. doi:10.1007/s40265-015-0463-1
Goldfarb DS, Corbett AH, Mason DA, Harreman MT, Adam SA (2004) Importin alpha: a multipurpose nuclear-transport receptor. Trends Cell Biol 14(9):505–514
Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY (2006) Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 173(6):607–616
Hakim A, Barnes PJ, Adcock IM, Usmani OS (2013) Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. FASEB J 27:4510–4519
Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M, Helgadottir H, Gudmundsdottir AS, Andrason H, Adalsteinsdottir AE, Kristjansson K, Birkisson I, Arnason T, Andresdottir M, Gislason D, Gislason T, Gulcher JR, Stefansson K (2005) Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A 102(41):14789–14794
Haque R, Hakim A, Moodley T, Torrego A, Essilfie-Quaye S, Jazrawi E, Johnson M, Barnes PJ, Adcock IM, Usmani OS (2013) Inhaled long-acting beta agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J Allergy Clin Immunol. doi:10.1016/j.jaci.2013.07.038
Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23(4):235–256
Hew M, Bhavsar P, Torrego A, Meah S, Khorasani N, Barnes PJ, Adcock I, Chung KF (2006) Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 174:134–141
Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM (2002) p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109(4):649–657
Ismaili N, Garabedian MJ (2004) Modulation of glucocorticoid receptor function via phosphorylation. Ann N Y Acad Sci 1024:86–101
Ito K, Barnes PJ, Adcock IM (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1b-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20:6891–6903
Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi M, Adcock IM, Hogg JC, Barnes PJ (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352:1967–1976
Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kB suppression. J Exp Med 203:7–13
John S, Sabo PJ, Johnson TA, Sung MH, Biddie SC, Lightman SL, Voss TC, Davis SR, Meltzer PS, Stamatoyannopoulos JA, Hager GL (2008) Interaction of the glucocorticoid receptor with the chromatin landscape. Mol Cell 29(5):611–624
Kadmiel M, Cidlowski JA (2013) Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 34(9):518–530. doi:10.1016/j.tips.2013.07.003
Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542–548
Kino T, Su YA, Chrousos GP (2009) Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci 66(21):3435–3448. doi:10.1007/s00018-009-0098-z
Kleiman A, Tuckermann JP (2007) Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 275(1-2):98–108
Kobayashi Y, Mercado N, Barnes PJ, Ito K (2011) Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma. PLoS One 6(12), e27627
Lane SJ, Arm JP, Staynov DZ, Lee TH (1994) Chemical mutational analysis of the human glucocortiocoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Respir Cell Mol Biol 11:42–48
Leaker BR, O’Connor B, Singh D, Barnes PJ (2015) The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma. J Allergy Clin Immunol. doi:10.1016/j.jaci.2015.01.034
Li LB, Goleva E, Hall CF, Ou LS, Leung DY (2004) Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 114(5):1059–1069
Mak JCW, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ (1995) Protective effects of a glucocorticoid on down-regulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 96:99–106
Maneechotesuwan K, Supawita S, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ (2008) Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. J Allergy Clin Immunol 121:43–50
Maneechotesuwan K, Yao X, Ito K, Jazrawi E, Usmani OS, Adcock IM, Barnes PJ (2009) Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 6(5), e1000076
Marwick JA, Caramori G, Stevenson CC, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A (2009) Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 179:542–548
Matthews JG, Ito K, Barnes PJ, Adcock IM (2004) Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 113(6):1100–1108
Medicherla S, Fitzgerald M, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS (2007) p38a Selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 324:921–929
Mercado N, To Y, Kobayashi Y, Adcock IM, Barnes PJ, Ito K (2011) p38 MAP kinase-g Inhibition by long-acting b2 adrenergic agonists reversed steroid insensitivity in severe asthma. Mol Pharmacol 80:1128–1135
Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF, Barnes PJ, Ito K (2012) Restoration of corticosteroid sensitivity by p38 mitogen activated Protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS One 7(7), e41582
Mitani A, Ito K, Vuppusetty C, Barnes PJ, Mercado N (2016) Inhibition of mTOR restores corticosteroid sensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 193(2):143–153
Nannini LJ, Poole P, Milan SJ, Kesterton A (2013) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 8, Cd006826. doi:10.1002/14651858.CD006826.pub2
Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E (2010) The human glucocorticoid receptor: molecular basis of biologic function. Steroids 75(1):1–12
O’Byrne PM, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, Pauwels RA (2006) Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 129(6):1478–1485
Osoata G, Yamamura S, Ito M, Vuppusetty C, Adcock IM, Barnes PJ, Ito K (2009) Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun 384:366–371
Polosa R, Thomson NC (2012) Smoking and asthma: dangerous liaisons. Eur Respir J 41:716–726
Postma DS, Rabe KF (2015) The asthma-COPD overlap syndrome. N Engl J Med 373(13):1241–1249. doi:10.1056/NEJMra1411863
Prabhala P, Ammit AJ (2015) Tristetraprolin and its role in regulation of airway inflammation. Mol Pharmacol 87(4):629–638. doi:10.1124/mol.114.095984
Pujols L, Mullol J, Picado C (2007) Alpha and beta glucocorticoid receptors: relevance in airway diseases. Curr Allergy Asthma Rep 7(2):93–99
Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF Jr, Levy ML, O’Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiroz M, Szefler SJ, Wong GW, FitzGerald JM (2015) A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 46(3):622–639. doi:10.1183/13993003.00853-2015
Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL (2002) Interaction between glucocorticoids and b2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360(9342):1293–1299
Sher ER, Leung YM, Surs W, Kam JC, Zieg G, Kamada AK, Szefler SJ (1994) Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 93:33–39
Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, Lafferty J, Chaudhuri R, Braganza G, Adcock IM, Barnes PJ, Wood S, Thomson NC (2009) Effect of theophylline plus beclometasone on lung function in smokers with asthma – a pilot study. Eur Respir J 33:1010–1017
Suissa S, Barnes PJ (2009) Inhaled corticosteroids in COPD: the case against. Eur Respir J 34(1):13–16
Tao T, Lan J, Lukacs GL, Hache RJ, Kaplan F (2006) Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells. Am J Respir Cell Mol Biol 35(6):668–680
To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliot M, Hogg JC, Adcock IM, Barnes PJ (2010) Targeting phosphoinositide-3-kinase-d with theophylline reverses corticosteroid insensitivity in COPD. Am J Respir Crit Care Med 182:897–904
Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM (2005) Glucocorticoid receptor nuclear translocation in airway cells following inhaled combination therapy. Am J Respir Crit Care Med 172:704–712
Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R (2013) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 187:347–365
Weigel NL, Moore NL (2007) Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 21(10):2311–2319
Yang IA, Clarke MS, Sim EH, Fong KM (2012) Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 7, CD002991
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Barnes, P.J. (2016). Glucocorticosteroids. In: Page, C., Barnes, P. (eds) Pharmacology and Therapeutics of Asthma and COPD. Handbook of Experimental Pharmacology, vol 237. Springer, Cham. https://doi.org/10.1007/164_2016_62
Download citation
DOI: https://doi.org/10.1007/164_2016_62
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52173-2
Online ISBN: 978-3-319-52175-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)